Get 50% OFF This Monsoon!
Nureca
No Stocks
Unlock Smart Score
See Detailed Analysis & Insights
Unlock Insights
See Detailed Analysis & Insights
No Research Report
ROE
Avg ROE (3 Yrs) : NaN%
ROCE
Avg ROCE (3 Yrs) : NaN%
ROA
Avg ROA (3 Yrs) : NaN%
NPM
Avg NPM (3 Yrs) : NaN%
Unlock Management Data
See Detailed Analysis & Insights
The Company was formerly incorporated as Nureca Private Limited in India on 02 November 2016 under the provisions of Companies Act, 2013. The Company got converted from Private Limited Company to a Public Limited Company with effect from 08 July 2020 and the name of Company was changed to Nureca Limited. The Company is engaged in the business of home healthcare and wellness products.
The Company is a leading healthcare and wellness company with a product range of over 150 SKUs across different categories. The flagship brands such as Dr. Trust continue to enjoy high credibility and a loyal customer base. The products comply with USFDA, European CE, ROHS and ISO certifications, which reinforce customer's belief in their products. At present, the Company holds more than 100 design products. Nureca is a digital first, B2C company. The Company sell products through implementation of various digital online platform channels like Flipkart, Amazon and website http://drtrust.in/. Dr. Trust is a pioneer in global healthcare and wellness brand with patented technologies and innovative solutions, helping users monitor chronic ailments. The Company is committed to creating products that support diagnosis, treatment and prevention of illness through monitoring and analysis of health data. Nureca's products are manufactured to be safe, accurate, long-lasting, and compliant with national and international regulations. The Company's growing range of connected devices is well entrenched in IoT and easy to sync with smart devices, while health app provides secure consolidation of data.
The Company is focused on leveraging its innovation, research, and data science capabilities to help and empower more people living with chronic and lifestyle diseases to live healthier and happier lives. The Company envisaged digital ecosystem and principles aims to provide integrated solutions aiding customers to maintain a suitable fitness regime, have clear understanding of and control over existing diseases with easier health monitoring at home and optimum nutrition through quality nutraceuticals.
In 2017, the Company commenced business operations and launched 'Dr. Trust' brand through digital healthcare channel.
In 2018, the Company widened product basket with launching of brands in electric massages and mother & child care categories like Dr. Physio and Trumom. The Company started three flex centers in Punjab, Karnataka and Uttar Pradesh.
In 2019, the Company took the initiative for commencing business with WS retail. It increased the aggregate number of SKUs to 150. The Company added three flex centers in Tricity Chandigarh, Telangana and Maharashtra. The Company's key products secured a warehouse drug license.
In 2020, Company expanded presence through different channels and took initiative for starting business with 1mg, Pharmeasy, Paytm, and Croma retail stores.
The Company had taken the effect of demerger as per the Scheme of Arrangement among Nectar Biopharma Private Limited (demerged company) and Nureca Private Limited (resulting company) and their respective shareholders and creditors under Section 230 to 232 and other applicable provisions of the Companies Act 2013, which has been sanctioned by the Honorable National Company Law Tribunal (NCLT), Mumbai vide its Order dated 29 April 2020. The Scheme had become effective on 23 May 2020 (Effective date) on filing of certified copy of the Order with the Registrar of Companies. The Appointed Date from which the Scheme was operative was 1 April 2019. Pursuant to the Scheme of Demerger, certain portion of business activities of the demerged company was transferred by Nectar Biopharma Private Limited from the Appointed date of 1 April 2019.
In FY 2021, the Company received prestigious 'Economic Times Best Healthcare Brands Award 2021'.
Nureca share price reflects investor sentiment toward the company and is impacted by various factors such as financial performance, market trends, and economic conditions. Share price is an indicator which shows the current value of the company's shares at which buyers or sellers can transact.
Market capitalization of Nureca indicates the total value of its outstanding shares. Marketcap is calculated by multiplying share price and outstanding shares of the company. It is a helpful metric for assessing the company's size and market Valuation. It also helps investors understand how Nureca is valued compared to its competitors.
Nureca PE ratio helps investors understand what is the market value of each stock compared to Nureca 's earnings. A PE ratio higher than the average industry PE could indicate an overvaluation of the stock, whereas a lower PE compared to the average industry PE could indicate an undervaluation.
The PEG ratio of Nureca evaluates its PE ratio in relation to its growth rate. A PEG ratio of 1 indicates a fair value, a PEG ratio of less than 1 indicates undervaluation, and a PEG ratio of more than 1 indicates overvaluation.
Return on Equity (ROE) measures how effectively Nureca generates profit from shareholders' equity. A higher ROE of more than 20% indicates better financial performance in terms of profitability.
Return on Capital Employed (ROCE) evaluates the profitability of Nureca in relation to its capital employed. In simple terms, ROCE provides insight to investors as to how well the company is utilizing the capital deployed. A high ROCE of more than 20% shows that the business is making profitable use of its capital.
Total debt of Nureca shows how much the company owes to either banks or individual creditors. In simple terms, this is the amount the company has to repay. Total debt can be a very useful metric to show the financial health of the company. Total debt more than equity is considered to be a bad sign.
The Debt-to-Equity (DE) ratio of Nureca compares its total debt to shareholders' equity. A higher Debt to Equity ratio could indicate higher financial risk, while a lower ratio suggests that the company is managing its debt efficiently.
CAGR shows the consistent growth rate of Nureca over a specific period, whether it is over a month, a year, or 10 years. It is a key metric to evaluate the company’s long-term growth potential. Main metrics for which CAGR is calculated are net sales, net profit, operating profit, and stock returns.
Technical analysis of Nureca helps investors get an insight into when they can enter or exit the stock. Key components of Nureca Technical Analysis include:
There are usually multiple support levels, but the main support levels for a stock are S1, S2, S3. Support levels indicate price points where stock might get support from buyers, helping the stock stop falling and rise.
There are usually multiple resistance levels, but the main resistance levels for a stock are R1, R2, R3. Resistance levels represent price points where Nureca shares often struggle to rise above due to selling pressure.
Dividends refer to the portion of the company’s profits distributed to its shareholders. Dividends are typically paid out in cash and reflect Nureca ’s financial health and profitability.
Bonus shares are usually given by companies to make the stock more affordable, increase liquidity, boost investor confidence, and more.
Stock split increases the number of its outstanding shares by dividing each existing share into multiple shares. When the company offers a stock split, the face value of the stock reduces in the same proportion as the split ratio.
The financials of Nureca provide a complete view to investors about its net sales, net profit, operating profits, expenses, and overall financial health. Investors can analyze financial data to assess the company’s stability and also understand how the company has been growing financially.
The profit and loss statement of Nureca highlights its net sales, net profit, total expenditure, and operating profits in the current financial year. This Profit and Loss statement is crucial for evaluating the profitability and financial stability of Nureca .
The balance sheet presents a snapshot of Nureca ’s assets, liabilities, and equity of shareholders, providing insights into the financials of the company.
Cashflow statements track the company's cash inflows and outflows over a period. It is an essential tool for understanding how well the company manages its liquidity and finances.
Download the App